Novantrone (Mitoxantrone)

Mitoxantrone intercalates into DNA and blocks topoisomerase II activity, preventing the resealing of DNA strands during replication. This results in double‑strand breaks and triggers apoptosis of rapidly dividing cells, such as cancerous and immune‑mediated cells.

The dosing regimen for Novantrone is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment protocol. Only a qualified healthcare professional should determine the appropriate dose.

Novantrone is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated in pregnant women and should not be used while breastfeeding because it can be excreted in milk and may harm the infant.

To request Novantrone, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Novantrone belongs to the anthracenedione class and differs from anthracyclines such as doxorubicin by its distinct DNA intercalation profile and a lower incidence of certain cardiotoxic effects at equivalent doses. However, both share risks of myelosuppression and require careful cardiac monitoring.

Novantrone must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability and potency.

Novantrone is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a prescribed period of time, using aseptic technique and appropriate infusion equipment.

The most serious risks include cardiotoxicity (reduced heart function), secondary acute leukemia, severe infections due to profound neutropenia, and rare hepatic or pulmonary toxicity. Patients should be monitored closely for these events throughout therapy.

Novantrone is contraindicated in patients with known hypersensitivity to mitoxantrone or any component of the formulation, in pregnant women, and in individuals with pre‑existing severe cardiac dysfunction. Caution is also advised for patients with uncontrolled infections or significant hepatic impairment.